Tokyo Tape
Sign in
← Nipro

Half-year report · Q2

8086.TEDINET S100UQIB
Period2024-04-01 → 2024-09-30
Filed2024-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 47
MetricValuePeriodScopeSource row
Revenue¥312.0bn2024-04-01 → 2024-09-30Cons.Net sales
Revenue¥586.8bn2023-04-01 → 2024-03-31Cons.Net sales (5-year summary)
Revenue¥285.9bn2023-04-01 → 2023-09-30Cons.Net sales
Operating income¥13.5bn2024-04-01 → 2024-09-30Cons.Operating income
Operating income¥13.5bn2023-04-01 → 2023-09-30Cons.Operating income
Ordinary income¥4.5bn2024-04-01 → 2024-09-30Cons.Ordinary income
Ordinary income¥19.5bn2023-04-01 → 2024-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥14.7bn2023-04-01 → 2023-09-30Cons.Ordinary income
Profit before tax¥4.1bn2024-04-01 → 2024-09-30Cons.Income before income taxes
Profit before tax¥17.5bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Net income (owners)¥129m2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥11.1bn2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥9.9bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income¥813m2024-04-01 → 2024-09-30Cons.Profit loss
Net income¥10.4bn2023-04-01 → 2023-09-30Cons.Profit loss
Total assets¥1.17Tat 2024-09-30Cons.Assets
Total assets¥1.11Tat 2024-03-31Cons.Assets
Total assets¥1.10Tat 2023-09-30Cons.Total assets (5-year summary)
Total liabilities¥875.4bnat 2024-09-30Cons.Liabilities
Total liabilities¥840.0bnat 2024-03-31Cons.Liabilities
Net assets / equity¥298.1bnat 2024-09-30Cons.Net assets
Net assets / equity¥269.8bnat 2024-03-31Cons.Net assets
Net assets / equity¥274.0bnat 2023-09-30Cons.Net assets (5-year summary)
Cash and deposits¥92.6bnat 2024-09-30Cons.Cash and deposits
Cash and deposits¥99.7bnat 2024-03-31Cons.Cash and deposits
Cash & equivalents¥85.0bnat 2024-09-30Cons.Cash and cash equivalents
Cash & equivalents¥96.6bnat 2024-03-31Cons.Cash and cash equivalents
Cash & equivalents¥83.8bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥84.7bnat 2023-03-31dCons.Cash and cash equivalents
Operating cash flow¥15.0bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥72.9bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥18.7bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥54.8bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥87.1bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥35.5bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Financing cash flow¥23.3bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities
Financing cash flow¥22.1bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥8.9bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥0.792024-04-01 → 2024-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥68.122023-04-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥60.892023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥0.72024-04-01 → 2024-09-30Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥60.352023-04-01 → 2024-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥53.952023-04-01 → 2023-09-30Cons.Diluted earnings per share (5-year summary)
Equity ratio22.1%at 2024-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio21.0%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio21.6%at 2023-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 54
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2024-04-01 → 2024-09-30¥3.0bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2024-04-01 → 2024-09-30¥383m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2024-04-01 → 2024-09-30¥2.6bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2024-04-01 → 2024-09-30−¥272m
Reconciling Itemsreconcilingrevenue2024-04-01 → 2024-09-30−¥39.9bn
Reconciling Itemsreconcilingrevenue intersegment2024-04-01 → 2024-09-30−¥39.9bn
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-09-30−¥14.9bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentrevenue2024-04-01 → 2024-09-30¥245.6bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentrevenue external2024-04-01 → 2024-09-30¥242.1bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥3.6bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentsegment profit2024-04-01 → 2024-09-30¥24.5bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentrevenue2024-04-01 → 2024-09-30¥68.4bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentrevenue external2024-04-01 → 2024-09-30¥38.0bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥30.4bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentsegment profit2024-04-01 → 2024-09-30¥3.2bn
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentrevenue2024-04-01 → 2024-09-30¥34.9bn
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentrevenue external2024-04-01 → 2024-09-30¥31.6bn
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥3.3bn
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentsegment profit2024-04-01 → 2024-09-30¥931m
—segment totalrevenue2024-04-01 → 2024-09-30¥348.9bn
—segment totalrevenue external2024-04-01 → 2024-09-30¥311.6bn
—segment totalrevenue intersegment2024-04-01 → 2024-09-30¥37.3bn
—segment totalsegment profit2024-04-01 → 2024-09-30¥28.7bn
Total Of Reportable Segments And Otherssegment totalrevenue2024-04-01 → 2024-09-30¥351.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2024-04-01 → 2024-09-30¥312.0bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2024-04-01 → 2024-09-30¥39.9bn
Total Of Reportable Segments And Otherssegment totalsegment profit2024-04-01 → 2024-09-30¥28.4bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-04-01 → 2023-09-30¥2.5bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-04-01 → 2023-09-30¥417m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-04-01 → 2023-09-30¥2.0bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-04-01 → 2023-09-30−¥109m
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥36.1bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥36.1bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥14.1bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentrevenue2023-04-01 → 2023-09-30¥223.6bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentrevenue external2023-04-01 → 2023-09-30¥220.2bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥3.3bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentsegment profit2023-04-01 → 2023-09-30¥22.6bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentrevenue2023-04-01 → 2023-09-30¥62.9bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentrevenue external2023-04-01 → 2023-09-30¥35.2bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥27.6bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentsegment profit2023-04-01 → 2023-09-30¥3.7bn
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentrevenue2023-04-01 → 2023-09-30¥33.0bn
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentrevenue external2023-04-01 → 2023-09-30¥30.0bn
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥3.1bn
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentsegment profit2023-04-01 → 2023-09-30¥1.4bn
—segment totalrevenue2023-04-01 → 2023-09-30¥319.5bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥285.4bn
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥34.0bn
—segment totalsegment profit2023-04-01 → 2023-09-30¥27.7bn
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-09-30¥321.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-09-30¥285.9bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-09-30¥36.1bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-09-30¥27.6bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 641
ItemContextValueUnit
Dividends income noiCurrentYTDDuration422000000JPY
Foreign exchange gains noiPrior1YTDDuration3604000000JPY
Foreign exchange gains noiCurrentYTDDuration－JPY
Other noiPrior1YTDDuration1259000000JPY
Other noiCurrentYTDDuration1192000000JPY
Non operating incomePrior1YTDDuration6061000000JPY
Non operating incomeCurrentYTDDuration2607000000JPY
Interest expenses noePrior1YTDDuration2847000000JPY
Interest expenses noeCurrentYTDDuration3717000000JPY
Foreign exchange losses noePrior1YTDDuration－JPY
Foreign exchange losses noeCurrentYTDDuration4700000000JPY
Equity in losses of affiliates noePrior1YTDDuration949000000JPY
Equity in losses of affiliates noeCurrentYTDDuration1461000000JPY
Other noePrior1YTDDuration1017000000JPY
Other noeCurrentYTDDuration1695000000JPY
Non operating expensesPrior1YTDDuration4813000000JPY
Non operating expensesCurrentYTDDuration11574000000JPY
Ordinary incomePrior1YTDDuration14736000000JPY
Ordinary incomeCurrentYTDDuration4492000000JPY
Gain on sales of noncurrent assets eiPrior1YTDDuration812000000JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration20000000JPY
Gain on sales of investment securities eiPrior1YTDDuration3682000000JPY
Gain on sales of investment securities eiCurrentYTDDuration143000000JPY
State subsidy eiPrior1YTDDuration367000000JPY
State subsidy eiCurrentYTDDuration2000000JPY
Other eiPrior1YTDDuration251000000JPY
Other eiCurrentYTDDuration14000000JPY
Extraordinary incomePrior1YTDDuration5112000000JPY
Extraordinary incomeCurrentYTDDuration179000000JPY
Loss on retirement of noncurrent assets elPrior1YTDDuration306000000JPY
Loss on retirement of noncurrent assets elCurrentYTDDuration124000000JPY
Loss on product recall elPrior1YTDDuration－JPY
Loss on product recall elCurrentYTDDuration201000000JPY
Loss on sale of investment in affiliated companies elPrior1YTDDuration1605000000JPY
Loss on sale of investment in affiliated companies elCurrentYTDDuration－JPY
Other elPrior1YTDDuration481000000JPY
Other elCurrentYTDDuration296000000JPY
Extraordinary lossPrior1YTDDuration2393000000JPY
Extraordinary lossCurrentYTDDuration621000000JPY
Income before income taxesPrior1YTDDuration17455000000JPY
Income before income taxesCurrentYTDDuration4051000000JPY
Income taxes currentPrior1YTDDuration7242000000JPY
Income taxes currentCurrentYTDDuration2913000000JPY
Income taxes deferredPrior1YTDDuration-197000000JPY
Income taxes deferredCurrentYTDDuration324000000JPY
Income taxesPrior1YTDDuration7044000000JPY
Income taxesCurrentYTDDuration3237000000JPY
Profit lossPrior1YTDDuration10410000000JPY
Profit lossCurrentYTDDuration813000000JPY
Profit loss attributable to non controlling interestsPrior1YTDDuration479000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2024-03-31pass rounding
balance sheet identityconsolidated 2024-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net assetsconsolidated 2024-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass